0.1680 -0.00 (-0.88%)
After hours: 6:38PM EST
|Bid||0.1689 x 1200|
|Ask||0.1693 x 45100|
|Day's Range||0.1590 - 0.1740|
|52 Week Range||0.1400 - 2.4500|
|Beta (5Y Monthly)||1.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.97|
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that management will present an update on the Company's business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 3:00 p.m. EST / 12:00 p.m. PST.
By John Vandermosten, CFA NASDAQ:TTNP READ THE FULL TTNP RESEARCH REPORT Third Quarter 2019 Financial and Operational Results During the third quarter and to date, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has expanded its network to include CVS Caremark, raised additional capital to support its sales and marketing efforts, received approval for additional NIDA funding and presented a pair of
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the third quarter ended September 30, 2019 and provided an update ...
SOUTH SAN FRANCISCO, Calif. , Nov. 7, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will announce its third quarter 2019 financial results after market close on Thursday, November 14, ...
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has two poster presentations on Probuphine (buprenorphine) implant, Titan's novel 6-month maintenance treatment for Opioid Use Disorder ("OUD") in eligible patients, at the 10th American Conference on Pharmacometrics taking place on October 20-23, 2019 in Orlando, FL. The poster presentations will provide details of the results from computer modeling studies that assessed the population pharmacokinetic ("PK") parameters, exposure-response profiles, and drug-drug interaction ("DDI") potential of the patient plasma levels of buprenorphine during treatment with Probuphine subdermal implants.
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced the pricing of an underwritten public offering of 40,000,000 units at a price to the public of $0.225 per unit. Each unit issued in the offering consists of one share of common stock (or pre-funded warrant in lieu thereof) and one Class B Warrant to purchase one share of common stock. The Class B Warrants will be immediately exercisable at a price of $0.225 per share of common stock and will expire five years from the date of issuance.
SOUTH SAN FRANCISCO, Calif., Oct. 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) and Crossroads of Southern Nevada ("Crossroads") rehabilitation facility today announced that Crossroads has healthcare providers who are specially trained in the insertion and removal of Probuphine® (buprenorphine) implants, and will now offer Probuphine for use in eligible patients with Opioid Use Disorder (OUD). Based in Las Vegas, Crossroads is a drug and alcohol rehabilitation center licensed by the State of Nevada and its Substance Abuse Prevention and Treatment Agency (SAPTA). "We are excited that Crossroads is implementing Probuphine as part of their comprehensive OUD treatment program," said Titan's Executive Vice President and Chief Commercial Officer, Dane Hallberg.
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 /PRNewswire/ -- National Institutes of Health's National Institute on Drug Abuse (NIDA) has approved approximately $6.1 million in second-year funding for Titan's non-clinical development of a ProNeura™ based six-month implantable formulation of Nalmefene, an opioid antagonist, intended for the prevention of relapse to opioid addiction, following opioid detoxification. NIDA awarded Titan a two-year grant in the amount of $6.7 million in September 2018 for the project, subject to satisfactory project progress, fund availability and certain other conditions. As a result of a change in the grant award terms regarding company matching funds, the second-year award covers both the Federal and company match amounts of the original year two award, thereby increasing the aggregate potential expense reimbursement to approximately $8.7 million.
Despite several factors in its favor including global expansion and repeat patients, second quarter revenues for Titan Pharmaceuticals, Inc. (TTNP) disappointed and missed our modest growth estimates. Despite an opioid epidemic where almost 70,000 people1 are dying annually, and two million2 are addicted in the United States, sales have languished at around $300,000, despite entering the third year of approval for the ProNeura implant. Titan has taken several steps to advance the commercialization of Probuphine, forging partnerships with AllianceRx to help with payors and fulfillment, with AppianRx to provide patient support and with Accredo for product inventory management, billing and payment as well as deep relationships with third party payors.
Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) Novocure Ltd (NASDAQ: NVCR ) Down In The Dumps (Biotech ...
SOUTH SAN FRANCISCO, Calif. , Aug. 14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the second quarter ended June 30, 2019 and provided an update ...
On Wednesday, August 14, Titan Pharmaceuticals (NASDAQ: TTNP ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Wall Street analysts see Titan ...
SOUTH SAN FRANCISCO, Calif. , Aug. 9, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will announce its second quarter 2019 financial results after market close on Wednesday, August 14, ...
SOUTH SAN FRANCISCO, Calif., Aug. 7, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced it has entered into a securities purchase agreement with a single accredited institutional investor to purchase approximately $2.1 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and each warrant will be $0.75. Under the terms of the purchase agreement, Titan has agreed to sell 2,852,314 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof).
SOUTH SAN FRANCISCO, Calif., July 9, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has executed a specialty product distribution agreement with CVS Caremark, a subsidiary of CVS Health, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan's novel maintenance treatment for Opioid Use Disorder (OUD) in eligible patients. Titan expects the majority of Probuphine sales in the United States to be through the specialty pharmacy distribution model and expansion of its specialty pharmacy network is a key component of a commercial strategy aimed at facilitating patient access to treatment by streamlining the product ordering and fulfillment process.
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is a small-cap stock with a market capitalization of US$17m. While investors...
SOUTH SAN FRANCISCO, Calif., June 26, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that the European Commission ("EC") has approved Sixmo®-buprenorphine, the brand name for Probuphine® (buprenorphine) implant in the European Union ("EU"). The EC's decision, received today by Molteni, applies to all 28 EU member states, where Sixmo is now approved for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.
SOUTH SAN FRANCISCO, Calif., June 4, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has executed a pharmacy services agreement with Southside Specialty Pharmacy, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan's novel maintenance treatment for Opioid Use Disorder (OUD) in eligible patients. "We are looking forward to working with Titan to provide patients with a unique, long-term maintenance treatment option for OUD," said Southside's Chief Executive Officer, Amit Jain.
Several important events took place in the first quarter of 2019 for Titan Pharmaceuticals, Inc. (TTNP) which were reported in the May 15th press release and in a concurrently filed 10-Q. During the quarter, Titan recorded total revenues of $0.9 million compared to $1.1 million in comparable period last year. Highlights for the first quarter and year to date include partnerships with AllianceRx Walgreens Prime, AppianRx and Accredo specialty pharmacy.
On a per-share basis, the San Francisco-based company said it had a loss of 34 cents. The specialty pharmaceutical company posted revenue of $945,000 in the period. In the final minutes of trading on Wednesday, ...